Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Allele Capital is an advisory and merchant banking firm established around 2017, located in Lauderdale by the Sea, Florida. The firm focuses exclusively on the life sciences industry, providing a blend of proprietary investment and capital sourcing alongside strategic advisory services. Their mission is to assist clients in achieving their milestones and maximizing shareholder value through trusted partnerships and extensive industry knowledge.
As of now, Allele Capital operates with a team of experienced professionals, including co-founders Shawn Titcomb and Menachem Kranz, and has built a notable portfolio of life science companies. The firm has not publicly disclosed its assets under management (AUM) or fund sizes, but it is recognized for its deep vertical expertise and extensive relationships within the sector. Allele Capital has made significant strides in the life sciences space, supporting companies in navigating capital markets and enhancing investor engagement.
Allele Capital invests in private and public life science companies, concentrating on sectors such as neurology, rare diseases, oncology, and cardiovascular health. The firm specializes in various therapeutic modalities, including gene therapy, RNA therapeutics, small molecules, and biologics. Their investment strategy is designed to target companies capable of achieving initial liquidity, proof of concept, or valuation inflection points within 12 to 24 months from the time of investment.
In addition to capital investment, Allele Capital provides advisory services that help optimize business strategies and capital needs. They seek to partner with companies that value integrity and aim to make a meaningful impact on patient health. The firm’s approach combines deep sector knowledge with a strong network of key opinion leaders (KOLs), enhancing their ability to support portfolio companies effectively.
Allele Capital has a diverse portfolio of notable companies in the life sciences sector. Key investments include:
These companies represent a mix of public and private entities, showcasing Allele Capital's commitment to advancing innovative solutions in the life sciences.
Shawn Titcomb - Co-Founder and Chief Executive Officer. Shawn has extensive experience in the life sciences sector and has been instrumental in guiding companies through capital markets.
Menachem Kranz - Co-Founder and Partner. Menachem brings a wealth of knowledge in strategic advisory and capital raising, focusing on enhancing shareholder value for portfolio companies.
Matt Hughes - Managing Partner. Matt has a strong background in investment banking and advisory services, specializing in the life sciences industry.
To pitch to Allele Capital, founders should send an email to info@allelecapital.com. It is recommended to include a comprehensive pitch deck that outlines the business model, market opportunity, and financial projections. The firm appreciates clarity and detail in presentations.
Response times may vary, but founders should expect to hear back within a few weeks. Warm introductions are preferred, as they can enhance the likelihood of a favorable review.
Allele Capital runs a program under its own name, focusing on providing advisory and capital raising services to life sciences companies. This program is designed to assist both private and public companies in achieving their strategic goals and maximizing shareholder value.
In recent months, Allele Capital has actively engaged with several life sciences companies, providing advisory and investment services. Notable activities include supporting Movano Health and Coya Therapeutics in navigating capital markets and enhancing investor engagement. The firm continues to build its reputation as a key player in the life sciences investment space.
What are Allele Capital's investment criteria?
Allele Capital focuses on life science companies, particularly in neurology, rare diseases, oncology, and cardiovascular health. They look for companies that can achieve initial liquidity, proof of concept, or valuation inflection points within 12 to 24 months from investment.
How can I pitch to Allele Capital?
Founders can reach out via email at info@allelecapital.com. It is advisable to include a detailed pitch deck that outlines the business model, market opportunity, and financial projections.
What makes Allele Capital different from other investors?
Allele Capital combines investment with strategic advisory services, leveraging deep sector expertise and a strong network of key opinion leaders (KOLs) to support portfolio companies effectively.
What is the geographic focus of Allele Capital?
Allele Capital primarily invests in companies based in the United States, specifically within the life sciences sector.
What is the typical check size for investments?
While specific check sizes are not disclosed, Allele Capital targets companies that can achieve significant milestones within a relatively short timeframe, indicating a focus on impactful investments.
What kind of post-investment support does Allele Capital provide?
Allele Capital offers strategic advisory services, capital raising assistance, and access to their extensive network within the life sciences sector to help portfolio companies navigate challenges and optimize growth.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.